BioMedNewsBreaks — Panna Sharma, Lantern Pharma CEO, Says FDA’s Elsa AI Rollout Underscores Urgency to Modernize

Panna Sharma, CEO of Lantern Pharma, commented on the U.S. Food and Drug Administration’s launch of its new AI tool in PharmaVoice, stating: “The timeline is aggressive, especially given that the scope and rigor of the initial pilot testing wasn’t fully showcased, but this reflects the urgency FDA feels.” His remarks highlight the rapid pace at which the agency is moving to integrate artificial intelligence into its regulatory infrastructure.

The FDA officially announced the agency-wide deployment of Elsa, a generative AI tool designed to assist staff in reviewing clinical protocols, summarizing adverse events, comparing drug labels, and identifying inspection targets. Developed within a secure GovCloud environment, Elsa does not train on data from regulated industry, ensuring confidentiality and data integrity. FDA Commissioner Marty Makary said the rollout was completed ahead of schedule and under budget, calling it a key step in the agency’s broader push to enhance efficiency through advanced technologies.

To read the full article, visit https://ibn.fm/9Xxtm

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN